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ABSTRACT 
Background: Disturbances in one carbon metabolism may contribute to carcinogenesis by 
affecting methylation and synthesis of DNA. Choline and its oxidation product betaine are 
involved in this metabolism and can serve as alternative methyl group donors when folate 
status is low.  
Methods: We conducted a case-control study nested within the European Prospective 
Investigation into Cancer and Nutrition (EPIC), to investigate plasma concentrations of the 
methyl donors methionine, choline, betaine, and dimethylglycine (DMG) in relation to 
colorectal cancer (CRC) risk. Our study included 1,367 incident CRC cases (965 colon; 402 
rectum) and 2,323 controls matched by gender, age group, and study center. Multivariate-
adjusted odds ratios (OR) and 95% confidence intervals (CI) for CRC risk were estimated by 
conditional logistic regression comparing the fifth to the first quintile of plasma 
concentrations.  
Results: Overall, methionine (OR: 0.79, 95%CI: 0.63-0.99, P-trend=0.05), choline (OR: 0.77, 
95%CI: 0.60-0.99, P-trend=0.07), and betaine (OR: 0.85, 95%CI: 0.66-1.09, P-trend=0.06) 
concentrations were inversely associated with CRC risk of borderline significance. Among 
women, but not men, high choline concentration was associated with decreased CRC risk 
(OR: 0.62, 95%CI: 0.43-0.88, P-trend=0.01). In participants with folate concentration below 
11.3 nmol/L, high betaine concentration was associated with reduced CRC risk (OR: 0.71, 
95%CI: 0.50-1.00, P-trend=0.02), which was not observed for those having a higher folate 
status. Plasma DMG was not associated with CRC risk. 
Conclusions: Individuals with high plasma concentrations of methionine, choline, and 
betaine may be at reduced risk of colorectal cancer. 
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INTRODUCTION 
Colorectal cancer (CRC) is third most common cancer world-wide [1] and the second most 
commonly diagnosed cancer in Europe with 447,000 estimated new cases in the year 2012 
[2]. In 2011, the World Cancer Research Fund (WCRF) concluded that there is convincing 
evidence of physical activity and dietary fibre intake to protect against colorectal cancer, 
whereas red meat, processed meat, intake of ethanol from alcoholic drinks, as well as body 
fatness and abdominal fatness, are associated with increased colorectal cancer risk [3]. 
 One-carbon metabolism includes donors of methyl groups for DNA methylation and 
DNA synthesis, both of which are involved in carcinogenesis. The B-vitamin folate as well as 
related methyl group donors involved in one-carbon metabolism, are hypothesized to 
potentially affect DNA methylation status and thereby have the potential to prevent 
carcinogenesis [4]. Choline and its oxidation product betaine can not only serve as 
alternative methyl group donors for the remethylation of homocysteine to methionine 
during folate deficiency, but, unlike folate, also provide additional methyl-groups for the 
synthesis of formate in the mitochondria, which subsequently can be used for one-carbon 
transmethylation reactions in the cytosol, including those involved in the production of 
purines and thymidalate. Conversely, during choline deprivation, methyl groups from the 
methyl carrier folate are used [5-7].  
 Only a few studies with inconclusive results have reported on choline and betaine 
status in relation to CRC. One cross-sectional study suggested an inverse association 
between plasma concentrations of methionine and betaine and high-risk colorectal 
adenomas [8]. Dietary methionine intake was associated with decreased proximal CRC risk 
among men [9]. Another study supported a positive association between choline intake and 
colorectal adenoma in women [10]. However, null associations for dietary choline have been 
reported [11], and the majority of prospective cohort studies and population-based case-
control studies on dietary methionine and CRC do not suggest an association [9, 12-19].  The 
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association between plasma folate and CRC risk has been inconsistent in several studies [20-
25].  This relation has previously been investigated in the European Prospective Investigation 
into Cancer and Nutrition (EPIC), but no association of plasma folate with CRC risk was 
observed [26]. 
 We conducted a large population-based case-control study nested within the 
European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We investigated 
associations between plasma concentrations of methionine, choline, betaine, and 
dimethylglycine (DMG; the product of the enzymatic conversion from betaine), in relation to 
overall CRC risk, and risk of colon and rectum cancer separately. In view of the hypothesis 
that these alternative methyl group donors become particularly important when folate 
status is low, we evaluated whether the associations were different among individuals with 
high or low folate status. 
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SUBJECTS AND METHODS  
Study population  
The methods and design of the EPIC study have previously been described [27]. EPIC is a 
large-scale population based prospective cohort study designed to investigate the relation 
between diet, nutritional and metabolic characteristics, various lifestyle factors and the risk 
of cancer [27]. In brief, the EPIC cohort is based on participants recruited from 23 
collaborating centers in 10 European countries (Denmark, France, Germany, Greece, Italy, 
the Netherlands, Norway, Spain, Sweden and the United Kingdom).  
 Data were collected between 1992 and 1998 and included baseline dietary 
questionnaires, standardized questionnaires on various lifestyle factors and personal history, 
and anthropometric data according to a standard protocol. Anthropometric data were 
measured on almost all subjects, except in the French and Oxford cohorts where these data 
were measured only for a restricted number of participants, but additional self-reports were 
obtained from all individuals. In Norway only self-reports were available [28]. 
 
Collection of blood samples 
Blood samples were collected from 80% of the participants at baseline, and at least 30 mL 
was drawn from each of the participants, either non-fasting or fasting. The samples were 
then transported to local laboratories for processing and aliquoting. During transport they 
were stored at temperatures from 5°C to 10°C and protected from light exposure [29, 30]. 
Exceptions from this procedure were the EPIC-Oxford and EPIC-Norway centers, where 
whole blood samples were transported to a central laboratory via mail. The whole blood 
samples were protected from light, but were exposed to ambient temperatures for up to 48 
hours. As some B-vitamins and related metabolites are unstable under such conditions [31], 
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all EPIC-Oxford (55 cases, 107 controls) and EPIC-Norway (5 cases, 9 controls) samples were 
excluded from the present analyses [29].  
 
Storage of blood samples 
Separation of blood into fractions of 0.5 mL (serum, plasma, erythrocytes and buffy coat for 
DNA extraction) were done in all countries except Denmark and Sweden (constituting 38.4% 
of all participants) because the collection in these countries was initiated many years before 
the common EPIC protocol [32]. The fractions were placed into heat sealed straws and 
stored in liquid nitrogen at a temperature of - 196°C. Half of the samples were stored at 
local study centers and the other half at the EPIC biorepository at the International Agency 
for Research on Cancer (IARC; Lyon, France). Storage conditions in Denmark and Sweden are 
described elsewhere [28, 29].  
 
Follow up for cancer incidence 
Follow up in EPIC is mainly based on national population-based cancer registries (Denmark, 
Italy, Netherlands, Norway, Spain, Sweden and the United Kingdom). Other sources of CRC 
diagnosis were health insurance records, pathology registries or through self-reporting 
(France, Germany and Greece). Self-reported cancer cases were verified through pathology 
reports and physicians, available for at least 95% of the cases. In our study, time between 
inclusion and diagnosis of CRC varied from 3 days to 11.5 years (mean 3.7 years).  
 
Study design and selection of study subjects 
Case definition and selection 
We conducted a nested case-control study within the EPIC cohort. Colon cancer was defined 
as the ICD-10 (The 10th Revision of the International Statistical Classification of Diseases, 
Injury and Causes of Death) diagnosis C18.0-C18.7, as well as tumors that were overlapping 
 7 
or unspecified; C18.8 and C18.9. Overlapping tumors are defined, as malignant neoplasm of 
overlapping sites of colon, were the primary site of the tumor is impossible to define. 
Cancers of the rectum were defined as the diagnosis C19 or C20. CRC is defined as a 
combination of the colon and rectal cancer cases. The present study included 1,367 CRC 
cases (colon n = 965; rectum n = 402).  
 
Control selection 
For each identified cancer case, 1 to 2 controls were randomly selected from all cohort 
members with available blood samples who were alive and free of cancer (except non-
melanoma skin cancer) at the time of diagnosis of the index case. The controls were 
matched by gender, age group (±2.5 years), and study center, except for the Danish cases, 
which were post hoc matched [29]. 
 
Laboratory measurements 
Plasma methionine, choline, betaine, and DMG, were determined by a method based on 
normal-phase liquid chromatography and tandem mass spectrometry [33]. Plasma folate 
was determined by a Lactobacillus casei microbiological assay, adapted to a microtiter plate 
format and carried out by a robotic workstation (Micro-lab AT plus 2; Hamilton Bonaduz AG, 
[34]). In addition, SNPs of genes related to one-carbon metabolism were determined by 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry [35]. These 
included methylene-tetrahydrofolate reductase (MTHFR) 677C→T, MTHFR 1298A→C and 
betaine-homocysteine methyltransferase (BHMT) 742G→A. All laboratory analyses were 
performed at BEVITAL AS, Bergen, Norway. 
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Statistical methods 
Because distributions of plasma concentrations were right-skewed, differences between 
cases and controls of the measured one-carbon biomarkers were assessed non-
parametrically by Kruskal Wallis test. Categorical variables were evaluated by χ2 test and the 
remaining continuous variables (age (y), body mass index (BMI, kg/m²), total energy intake 
(kJ) and total meat intake (g/day)) by ANOVA. 
 Multivariate-adjusted odds ratios (OR) and 95% confidence intervals (CI) were 
estimated by conditional logistic regression for CRC risk in relation to quintiles of 
methionine, choline, betaine, and DMG concentrations, taking the lowest quintiles as 
reference categories. Quintile cut-off values were based on the distributions among controls. 
Tests for linear trend over quintiles were performed by fitting the ordinal exposure variables 
as continuous variables. These analyses were conducted for overall CRC and for colon and 
rectum cancer separately. To decrease the possibility of reverse causality we also conducted 
an analysis where we excluded the cases (n=163; 11.2%) diagnosed within the first year of 
follow up. We adjusted for potential confounders; Body Mass Index (BMI; kg/m2), smoking 
status (never, former and current), physical activity (inactive, moderately inactive, 
moderately active, and active), alcohol consumption (abstainers, >0 –<30g/day and 
≥30g/day), and dietary intake of fibre, red meat, processed meat, and total energy. 
 We also estimated ORs in analyses stratified for median time from blood donation 
to cancer diagnosis (below and above median follow up time of 3.6 years), sex, and age at 
recruitment (<60 years versus ≥ 60 years). In addition, unconditional logistic regression 
analyses were conducted, in which the matching criteria were included as covariates, in 
order to estimate interactions with sex and age category, and to estimate CRC risk for 
subgroups of median folate concentration (above and below median) among controls (<11.3 
nmol/L and ≥11.3 nmol/L).  
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 It could be expected that serum concentrations are differentially associated with 
cancer risk across the genotypes due to the influence on enzymatic activity. Therefore, in 
addition to previously reported associations of one-carbon genetic variants with CRC risk [26, 
36], we analysed the associations between BHMT (742GA) genotypes and CRC risk, and 
between serum concentrations with CRC risk across BHMT (742GA) as well as MTHFR 
(677CT and 1298AC) genotypes with CRC risk. 
 All statistical analyses were conducted using STATA, version 11. 
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RESULTS 
Characteristics of the study population 
Altogether, 1,367 cases and 2,323 matched controls were included in the analyses. Mean 
age at blood donation was 59.0 years and mean age at diagnosis was 62.7 years. Baseline 
characteristics of cases and controls are summarized in Table 1. BMI, current smoking, 
alcohol consumption, and meat intake were significantly higher among cases than controls, 
whereas fibre intake and the level of physical activity were lower among cases. Plasma 
concentrations of methionine, choline, betaine, and folate were lower among cases than 
among controls. However, genotype frequencies did not differ between cases and controls. 
 All four methyl group donors, methionine, choline, betaine, and DMG, showed 
higher median concentrations in men compared to women among controls (P<0.01). 
Furthermore, median concentrations of methionine were lower, and those of betaine, 
choline and DMG were higher in controls over the age of 60 (P<0.01) (data not shown). 
 
Associations between plasma concentrations of methyl group donors and CRC risk 
Analyses adjusted for BMI, smoking status, physical activity, alcohol consumption, and 
intake of fibre, red meat, processed meat, and energy, revealed that high methionine (OR: 
0.79, 95%CI: 0.63-0.99, P-trend=0.05), high choline (OR: 0.77, 95%CI: 0.60-0.99, P-
trend=0.07), and high betaine (OR: 0.85, 95%CI: 0.66-1.09, P-trend=0.06) concentrations 
were associated with lower CRC risk of borderline significance (Table 2). Exclusion of the 
cases diagnosed within the first year of follow-up modestly attenuated the associations of 
methionine and betaine, whereas choline remained associated with reduced CRC risk (P-
trend=0.05) (data not shown). 
 Choline was inversely associated with colon cancer risk, while we did not observe 
significant associations between the remaining plasma concentrations and risk of colon 
cancer or rectum cancer separately (Table 3). Plasma methionine was associated with 
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reduced CRC risk exclusively in those cases who were diagnosed with CRC within 3.6 years 
after blood collection, and not in those diagnosed at a later time. Choline, betaine, and DMG 
were not significantly associated with CRC risk in either of these groups (data not shown). 
       
Subgroup analysis 
Subgroup analysis (Table 4) revealed an inverse association between choline and CRC risk in 
women (OR: 0.62, 95%CI: 0.43-0.88, P-trend=0.01), but not in men (OR: 1.03, 95%CI: 0.71-
1.50, P-trend=0.87). The inverse associations of methionine and betaine were observed 
among individuals <60 years of age, but not among those ≥60 years. However, the tests for 
interaction, based on unconditional logistic regression models, were not significant for these 
associations. Further, an increased CRC risk for higher levels of DMG in the age group <60 
years was also present, whereas among those ≥60 years no association was observed.  
 In the analyses stratified by folate concentration, plasma betaine was inversely 
associated with CRC risk in the group with folate concentration below the median of 11.3 
nmol/L, but not among those with folate concentration above the median (Table 5). A 
similar, though borderline significant inverse association was observed for high choline 
concentrations among individuals with lower folate status. Neither methionine or choline, 
nor DMG were differentially associated with CRC risk across the categories of folate status. 
 
The polymorphisms and their association with CRC risk 
No associations between the genotypes and CRC risk or of serum concentrations across 
genotypes were observed (data not shown).  
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DISCUSSION  
In this large-scale population-based European nested case control study, we investigated 
plasma concentrations of methionine, choline, betaine, and DMG in relation to CRC risk. 
Overall, plasma methionine, choline, and betaine status were modestly inversely associated 
with CRC risk. Plasma choline was associated with reduced CRC risk among women, but not 
among men. The inverse assocations of methionine and betaine were confined to individuals 
<60 years at recruitment. Finally, we observed that higher betaine concentration was 
associated with a reduced CRC risk among individuals with folate concentration below the 
median of 11.3 nmol/L, but not among those with higher folate status. 
 This study is the largest prospective study on plasma methionine and the first on 
plasma DMG, choline and betaine concentrations in relation to CRC risk to date. The large 
sample size and extensive data collection on modifiable risk factors for CRC allowed 
subgroup analyses. Strength of this study is the nested case-control design, where blood 
samples were taken prior to cancer diagnosis. The mean time between inclusion and cancer 
diagnosis was relatively short (median 3.6 years), which may have led to reverse causality if 
undiagnosed (pre-clinical) cancer has affected exposure status. Although possibly resulting 
from reduced power to demonstrate an underlying true association, the inverse associations 
of methionine and betaine with CRC risk tended to attenuate after exclusion of cases 
diagnosed within the first year of follow up. Nevertheless, the possibility cannot be excluded 
that reverse causation has biased the estimated associations to some extent. Another 
advantage of our study was that the main exposure variables were measured in blood rather 
than obtained from dietary questionnaires [9-11, 17], which rely on subjects´ memory or 
ability in recording dietary intake [27].  
 In the EPIC study, extensive lifestyle factors and other relevant information have 
been collected for each cohort member, which allowed us to address potential confounders 
and assessment of potential effect modification. Potential confounders such as BMI, 
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smoking status, physical activity, alcohol consumption, and dietary intake of red meat, 
processed meat, fibre, and energy were adjusted for, but the results from this adjusted 
analysis were essentially the same as from the crude analyses. 
 The blood samples were collected according to a standardized protocol [27] at each 
study center and all the biochemical analysis were conducted at one laboratory, thereby 
eliminating variability in sampling procedures and assay methods. However, a possible 
drawback of a single blood sample is that it may not have captured long term plasma 
concentrations of each individual, and may therefore not represent lifetime exposure. 
Variations in plasma concentrations over time may occur due to life-style changes and diet 
variation. Further, the measured blood levels may not directly reflect the dietary intake or 
body stores of nutrients.  
Inverse associations between plasma levels or dietary intake of methionine and 
betaine with risk of colorectal adenomas (CRA) or CRC, were previously reported in a cross-
sectional analysis of the Norwegian Colorectal Cancer Prevention (NORCCAP) screening 
study [8] and the prospective Netherlands Cohort Study on diet and Cancer (NLCS) [9]. 
Conversely, a positive association between choline intake and CRA risk was previously 
observed in the Nurses Health Study [10]. However, one would expect high choline to be 
protective against neoplasia, as choline deficiency has the potential to induce DNA damage 
by uracil misincorporation and to alter DNA methylation patterns [37]. For instance, in an 
intervention study, subjects fed a choline deficient diet for 10 days had more subsequent 
DNA damage in lymphocytes compared to when taking the recommended daily intake of 
choline [38]. Furthermore, a recent population-based case-control study in China reported 
that, especially among former and current smokers, dietary choline and betaine intake was 
associated with reduced lung cancer risk [39].  
 Although not associated with overall CRC risk, we observed that high plasma choline 
may protect against CRC in women. This may be partly due to differences in the metabolism 
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of choline between men and women. Choline is not only obtained from the diet, but is also 
synthesized endogenously from phosphatidylethanolamine by the enzyme 
phosphatidylethanolamine-N-methyltransferase (PEMT), the activity of which is increased by 
estrogen [40]. This may explain why postmenopausal women tend to be less resistant 
against choline deficiency compared to premenopausal women [41]. Moreover, results from 
the Long Island Breast Cancer Study suggest that high dietary betaine and choline intakes 
were associated with decreased all-cause and breast cancer-specific mortality [42], and that 
rare variants of the PEMT rs12325817 SNP, which is associated with decreased choline 
biosynthesis, was associated with a 30% increased risk of breast cancer [42]. In our study, 
the majority of the women were postmenopausal, as mean age at inclusion in the EPIC 
cohort was 58.8 years and 58.6 years in cases and controls, respectively. We also observed 
that mean choline concentration was lower among women than among men in our study 
(data not shown), and women may therefore have benefited more from a high choline 
status.  
 When stratifying according to age at recruitment, the inverse associations of 
methionine and betaine were observed exclusively among participants <60 years at baseline 
whereas DMG was associated with increased CRC risk in this age group. These differences 
could not be explained by an underlying difference between the two age categories, with 
respect to the time between cohort inclusion and cancer diagnosis or large differences of 
the main exposure variables (data not shown). However, given that there was no statistically 
significant interaction observed for methionine and betaine, it may be questioned whether 
there has been a true age effect. Nevertheless, although speculative, individuals ≥60 years at 
baseline may have benefited less from higher plasma concentrations of the studied methyl 
group donors possibly partly because they had undiagnosed colorectal adenomas more 
often compared to the younger age group. In this respect, a large screening study of 
individuals 50-64 years of the general Norwegian population revealed that 17.1% of the 
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screened participants had at least one distal CRA [8], and this proportion is likely to increase 
with increasing age.  
 Although in the EPIC cohort plasma folate and vitamin B12 were not associated with 
CRC risk [26, 29], inverse associations were observed of plasma concentrations of vitamins 
B2 and B6 with CRC risk [29]. In addition, dietary intake of vitamins B2 and B6 were 
associated with reduced CRC risk in the Women's Health Initiative Observational Study [43]. 
B-vitamins are components of a network with major effects on the transfer of one-carbon 
units, as B-vitamins were more strongly related to plasma tHcy when concentrations of 
other B vitamins were low [44]. Similarly, choline and betaine may serve as alternative 
methyl group donors when folate status is low [7]. Our observation of a possible protective 
role of choline and betaine among individuals with lower folate status may support this 
possibility. 
 Finally, the number of CRC cases identified in the EPIC cohort so far may have been 
insufficient to demonstrate an association, if any, of BHMT genotypes in the current study, 
and of other related one-carbon genetic variants with CRC risk [26, 36]. 
  This study suggests that methionine, choline, and betaine may play a protective role 
in colorectal carcinogenesis and that these methyl group donors should be investigated 
further with respect to CRC risk. Repeated blood samples in order to more accurately reflect 
lifetime exposure could be an important focus for future research. A longer follow-up period 
is also recommendable to exclude the potential problem of reverse causality. 
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Table 1. Baseline characteristics of colorectal cancer cases and matched controls in the European Prospective Investigation 
into Cancer and Nutrition (EPIC) 
 Cases Controls P-difference 
No. of individuals 1,367 2,323  
Sex, female, n(%) 700 (51.2) 1,213 (52.2) 0.55* 
Age at recruitment (years; mean (SD)) 58.9 (7.1) 58.7 (7.5) 0.38§ 
Body Mass Index (kg/m2; mean(SD)) 26.8 (4.3) 26.4 (3.9) 0.005§ 
Smoking status, n (%)   0.05* 
     Never 561 (41.0) 1,025 (44.1)  
     Former 451 (33.0) 775 (33.4)  
     Current 346 (25.3) 510 (22.0)  
     Unknown 9 (0.7) 13 (0.6)  
Physical activity, n (%)   0.05* 
     Active 123 (9.0) 242 (10.4)  
     Moderately active 574 (42.0) 1,019 (43.9)  
     Moderately inactive 423 (30.9) 697 (30.0)  
     Inactive 219 (16.0) 304 (13.1)  
     Unknown 28 (2.1) 61 (2.6)  
Alcohol consumption, n(%)   0.001* 
     Abstainers 172 (12.6) 347 (14.9)  
     >0g/day and <30 g/day 908 (66.5) 1,597 (68.8)  
     ≥ 30 g/day 285 (20.9) 379 (16.3)  
Dietary intakes (mean (SD))    
     Energy (kcal/day) 2176 (710) 2136 (643) 0.08§ 
     Total meat (g/day) 118.3 (69.8) 109.7 (56.4) <0.001§ 
     Red meat (g/day) 53.9 (39.5) 47.5 (35.5) <0.001§ 
     Processed meat (g/day) 38.2 (47.8) 35.3 (32.2) 0.03 § 
     Fibre, mean (g/day) 22.2 (8.2) 22.9 (7.9) 0.003 § 
Plasma concentrations (median (5th-95th percentile))    
     Methionine (µmol/L) 23.7 (16.6-37.0) 24.2 (17.0-37.4) 0.009¶ 
     Choline (µmol/L) 9.3 (6.2-14.2) 9.4 (6.3-14.4) 0.02¶ 
     Betaine (µmol/L) 31.5 (18.4-52.6) 33.0 (18.5-53.8) 0.005¶ 
     Dimethylglycine (µmol/L) 3.6 (2.4-5.9) 3.6 (2.3-6.1) 0.86¶ 
     Folate (nmol/L) 10.9 (5.1-32.1) 11.3 (4.9-34.0) 0.03¶ 
MTHFR 677CT, %    0.86* 
     CC 41.8 42.7  
     CT 46.1 45.8  
     TT 12.1 11.6  
MTHFR 1298AC, %   0.96* 
     AA 45.9 45.8   
     AC 43.0 43.4   
     CC 11.1 10.8   
BHMT 742GA, %   0.45* 
     GG 50.8 48.6  
     GA 41.0 42.5  
     AA 8.2 8.8  
* Chi2-test, unknown category not included 
§ ANOVA 
¶ Kruskal Wallis test 
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Table 2. Conditional logistic regression analyses with corresponding odds (OR) ratios and 95% confidence intervals for 
colorectal cancer, according to quintiles of methionine, betaine, choline and dimethylglycine concentrations 
   OR ** 
Plasma concentration Quintiles (range) * cases/controls Crude analyses Adjusted analyses *** 
Methionine  1 (< 20.2) 335/465 Reference Reference 
(µmol/L) 2 (20.2 –< 22.9) 264/465 0.79 (0.63-0.97) 0.79 (0.63-0.98) 
 3 (22.9 –< 25.6) 260/464 0.81 (0.65-1.00) 0.83 (0.66-1.03) 
 4 (25.6 –< 29.6) 249/465 0.77 (0.61-0.96) 0.77 (0.61-0.97) 
 5 (≥ 29.6) 259/464 0.78 (0.62-0.98) 0.79 (0.63-0.99) 
   p-trend=0.04 p-trend=0.05 
     
Choline 1 (< 7.7) 317/460 Reference  Reference  
(µmol/L) 2 (7.7 –< 8.9) 268/472 0.84 (0.68-1.04) 0.83 (0.66-1.03) 
 3 (8.9 –< 10.1) 276/462 0.92 (0.73-1.15) 0.91 (0.73-1.15) 
 4 (10.1 –< 11.7) 254/457 0.86 (0.68-1.09) 0.82 (0.64-1.04) 
 5 (≥ 11.7) 250/472 0.84 (0.66-1.07) 0.77 (0.60-0.99) 
   p-trend=0.26 p-trend=0.07 
     
Betaine 1 (< 24.8) 297/461 Reference  Reference  
(µmol/L) 2 (24.8 –< 30.4) 304/469 1.01 (0.81-1.25) 1.03 (0.82-1.28) 
 3 (30.4 –< 35.3) 282/459 0.94 (0.76-1.17) 0.98 (0.79-1.22) 
 4 (35.3 –< 42.1) 246/468 0.79 (0.63-1.00) 0.84 (0.66-1.06) 
 5 (≥ 42.1) 236/466 0.78 (0.62-1.00) 0.85 (0.66-1.09) 
   p-trend=0.01 p-trend=0.06 
     
DMG 1 (< 2.9) 271/464 Reference  Reference  
(µmol/L) 2 (2.9 –< 3.3) 267/452 1.09 (0.87-1.36) 1.05 (0.84-1.31) 
 3 (3.3 –< 3.9) 288/473 1.15 (0.92-1.44) 1.12 (0.89-1.41) 
 4 (3.9 –< 4.6) 277/467 1.21 (0.96-1.51) 1.13 (0.89-1.42) 
 5 (≥ 4.6) 262/467 1.18 (0.93-1.50) 1.10 (0.86-1.40) 
   p-trend=0.12 p-trend=0.33 
* Quintiles are based on the distribution of serum concentrations among controls 
** Case-control matching factors included sex, age, and study center  
*** Adjusted for BMI, smoking status, physical activity and alcohol consumption 
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Table 3. Conditional logistic regression analyses with corresponding odds (OR) ratios and 95% confidence intervals for colon 
and rectum cancer, according to quintiles of methionine, betaine, choline and dimethylglycine concentrations 
  Colon cancer Rectum cancer 
 
Plasma concentration 
Quintiles (range) * cases/ 
controls 
OR ** cases/ 
controls 
OR ** 
Methionine 1 (< 20.2) 215/294 Reference  97/132 Reference  
(µmol/L) 2 (20.2 –< 22.9) 159/308 0.73 (0.56-0.94) 81/121 0.97 (0.64-1.47) 
 3 (22.9 –< 25.6) 172/305 0.85 (0.66-1.10) 68/121 0.77 (0.50-1.17) 
 4 (25.6 –< 29.6) 149/289 0.76 (0.58-1.00) 75/140 0.77 (0.50-1.19) 
 5 (≥ 29.6) 159/278 0.80 (0.61-1.06) 82/146 0.79 (0.52-1.19) 
   p-trend= 0.18  p-trend= 0.16 
      
Choline 1 (< 7.7) 207/281 Reference  92/140 Reference  
(µmol/L) 2 (7.7 –< 8.9) 158/298 0.79 (0.61-1.03) 82/139 0.95 (0.64-1.42) 
 3 (8.9 –< 10.1) 177/297 0.85 (0.65-1.11) 82/126 1.11 (0.73-1.71) 
 4 (10.1 –< 11.7) 155/299 0.75 (0.56-0.99) 79/124 1.04 (0.66-1.64) 
 5 (≥ 11.7) 156/299 0.74 (0.55-0.99) 67/131 0.87 (0.54-1.40) 
   p-trend= 0.05  p-trend= 0.76 
      
Betaine 1 (< 24.8) 206/291 Reference  73/118 Reference  
(µmol/L) 2 (24.8 –< 30.4) 184/299 0.97 (0.75-1.26) 100/144 1.22 (0.80-1.86) 
 3 (30.4 –< 35.3) 163/305 0.88 (0.68-1.14) 92/124 1.30 (0.85-1.98) 
 4 (35.3 –< 42.1) 152/285 0.86 (0.66-1.14) 69/140 0.81 (0.51-1.28) 
 5 (≥ 42.1) 148/294 0.84 (0.63-1.12) 68/134 0.89 (0.55-1.43) 
   p-trend= 0.16  p-trend=0.18 
      
DMG 1 (< 2.9) 182/292 Reference  74/128 Reference  
(µmol/L) 2 (2.9 –< 3.3) 170/306 1.01 (0.77-1.32) 76/108 1.14 (0.75-1.73) 
 3 (3.3 –< 3.9) 176/286 1.16 (0.89-1.51) 83/152 1.01 (0.66-1.56) 
 4 (3.9 –< 4.6) 178/300 1.09 (0.83-1.42) 77/126 1.23 (0.78-1.93) 
 5 (≥ 4.6) 147/290 1.02 (0.76-1.37) 92/146 1.28 (0.84-1.99) 
   p-trend= 0.67  p-trend= 0.25 
* Quintiles are based on the distribution of serum concentrations among controls 
** Case-control matching factors were sex, age, and study center. Adjusted for BMI, smoking status, physical activity, alcohol 
consumption, and intakes of energy, fibre, red meat, and processed meat 
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Table 4. Conditional  logistic regression analyses with corresponding odds (OR) ratios and 95% confidence intervals for colorectal cancer, according to quintiles of methionine, betaine, choline and 
dimethylglycine concentrations, by sex and age 
  Sex Age at recruitment 
  Men Women <60 years ≥60 years 
 
Plasma concentration 
 
Quintiles (range) * 
cases/ 
controls 
OR ** 
cases/ 
controls 
OR ** 
cases/ 
controls 
OR ** 
cases/ 
controls 
OR ** 
          
Methionine 1 (< 20.2) 130/170 Reference  205/295 Reference  165/230 Reference  170/235 Reference  
(µmol/L) 2 (20.2 –< 22.9) 106/190 0.73 (0.52-1.03) 158/275 0.84 (0.63-1.11) 139/257 0.75 (0.55-1.03) 125/208 0.86 (0.61-1.19) 
 3 (22.9 –< 25.6) 127/210 0.86 (0.61-1.21) 133/254 0.80 (0.59-1.07) 146/268 0.76 (0.56-1.04) 114/196 0.87 (0.62-1.22) 
 4 (25.6 –< 29.6) 145/260 0.78 (0.56-1.09) 104/205 0.75 (0.54-1.04) 148/255 0.80 (0.58-1.11) 101/201 0.68 (0.48-0.98) 
 5 (≥ 29.6) 159/280 0.75 (0.53-1.05) 100/184 0.85 (0.62-1.18) 131/267 0.64 (0.46-0.90) 128/197 1.03 (0.74-1.45) 
   P-trend=0.17  P-trend=0.17  P-trend=0.03  P-trend=0.69 
  P-interaction=0.91 *** P-interaction=0.32 *** 
Choline 1 (< 7.7) 110/185 Reference  207/275 Reference  200/312 Reference  117/148 Reference  
(µmol/L) 2 (7.7 –< 8.9) 131/194 1.18 (0.83-1.67) 137/278 0.65 (0.49-0.87) 152/269 0.85 (0.64-1.14) 116/203 0.76 (0.52-1.10) 
 3 (8.9 –< 10.1) 140/228 1.15 (0.81-1.65) 136/234 0.77 (0.57-1.04) 150/255 0.89 (0.66-1.22) 126/207 0.92 (0.64-1.33) 
 4 (10.1 –< 11.7) 138/241 1.06 (0.74-1.52) 116/216 0.67 (0.48-0.94) 116/239 0.73 (0.52-1.02) 138/218 0.93 (0.64-1.34) 
 5 (≥ 11.7) 148/262 1.03 (0.71-1.50) 102/210 0.62 (0.43-0.88) 109/202 0.77 (0.54-1.10) 141/270 0.75 (0.52-1.10) 
   P-trend=0.87  P-trend=0.01  P-trend=0.10  P-trend=0.40 
  P-interaction=0.11 *** P-interaction=0.58 *** 
Betaine 1 (< 24.8) 80/105 Reference  217/356 Reference  174/297 Reference  123/164 Reference  
(µmol/L) 2 (24.8 –< 30.4) 125/180 0.89 (0.60-1.32) 179/289 1.09 (0.83-1.42) 171/249 1.16 (0.86-1.56) 133/220 0.92 (0.65-1.31) 
 3 (30.4 –< 35.3) 148/229 0.90 (0.62-1.30) 134/230 1.01 (0.76-1.34) 155/247 1.01 (0.75-1.37) 127/212 0.92 (0.65-1.30) 
 4 (35.3 –< 42.1) 146/279 0.72 (0.49-1.06) 100/189 0.91 (0.66-1.26) 110/241 0.72 (0.51-1.01) 136/227 0.94 (0.66-1.34) 
 5 (≥ 42.1) 168/317 0.79 (0.54-1.15) 68/149 0.81 (0.56-1.19) 117/243 0.82 (0.58-1.17) 119/223 0.85 (0.58-1.25) 
   P-trend=0.11  P-trend=0.25  P-trend=0.03  P-trend=0.52 
  P-interaction=0.91 *** P-interaction=0.28 *** 
DMG 1 (< 2.9) 90/134 Reference  181/330 Reference  152/308 Reference  119/156 Reference  
(µmol/L) 2 (2.9 –< 3.3) 115/187 0.99 (0.68-1.46) 152/265 1.06 (0.80-1.41) 137/266 1.09 (0.80-1.47) 130/186 0.97 (0.67-1.41) 
 3 (3.3 –< 3.9) 142/232 1.05 (0.72-1.51) 146/241 1.17 (0.87-1.57) 151/268 1.19 (0.88-1.62) 137/205 1.08 (0.74-1.56) 
 4 (3.9 –< 4.6) 156/261 0.99 (0.69-1.44) 121/206 1.24 (0.91-1.69) 149/226 1.51 (1.10-2.07) 128/241 0.81 (0.56-1.19) 
 5 (≥ 4.6) 164/296 0.98 (0.67-1.42) 98/171 1.23 (0.87-1.74) 138/209 1.60 (1.14-2.24) 124/258 0.78 (0.53-1.15) 
   P-trend=0.89  P-trend=0.12  P-trend=0.001  P-trend=0.11 
  P-interaction=0.93 *** P-interaction=0.001 *** 
* Quintiles are based on the distribution of serum concentrations among controls 
** Case-control matching factors included sex, age, and study center. Adjusted for BMI, smoking status, physical activit, alcohol consumption, and intakes of energy, fibre, red meat, and processed meat 
***P-values for interaction are based on unconditional logistic regression with case-control matching factors modeled as co-variates, adjusted for BMI, smoking status, physical activity, alcohol consumption, and 
intakes of energy, fibre, red meat, and processed meat 
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Table 5. Logistic regression analyses with corresponding odds (OR) ratios and 95% confidence intervals for colorectal cancer, 
according to quintiles of methionine, betaine, choline and dimethylglycine concentrations, for low (under median of 11.3 
nmol/L) and high (above median) folate concentrations 
   
Folate <11.3 nmol/L 
 
 
Folate ≥11.3 nmol/L 
 
Plasma concentration 
Quintiles 
(range) * 
cases/ 
controls 
OR * 
cases/ 
controls 
OR * 
Methionine 1 (< 20.2) 170/218  Reference 165/245 Reference  
(µmol/L) 2 (20.2 –< 22.9) 139/228 0.76 (0.57-1.03) 125/235 0.81 (0.60-1.09) 
 3 (22.9 –< 25.6) 132/239 0.79 (0.55-1.01) 128/225 0.87 (0.64-1.17) 
 4 (25.6 –< 29.6) 133/239 0.73 (0.54-0.98) 116/225 0.79 (0.58-1.08) 
 5 (≥ 29.6) 147/232 0.76 (0.56-1.02) 112/232 0.76 (0.56-1.04) 
   P-trend=0.07  P-trend=0.11 
  P-interaction=0.85 
Choline 1 (< 7.7) 195/245 Reference  122/213 Reference  
(µmol/L) 2 (7.7 –< 8.9) 129/250 0.64 (0.48-0.86) 139/221 1.08 (0.79-1.48) 
 3 (8.9 –< 10.1) 148/227 0.80 (0.60-1.08) 128/234 0.95 (0.69-1.31) 
 4 (10.1 –< 11.7) 125/219 0.71 (0.52-0.96) 129/237 0.91 (0.66-1.26) 
 5 (≥ 11.7) 124/215 0.71 (0.52-0.96) 126/257 0.81 (0.58-1.13) 
   P-trend=0.07  P-trend=0.12 
  P-interaction=0.13 
Betaine 1 (< 24.8) 182/266 Reference  115/193 Reference  
(µmol/L) 2 (24.8 –< 30.4) 176/256 0.98 (0.75-1.30) 128/213 1.03 (0.74-1.42) 
 3 (30.4 –< 35.3) 147/232 0.89 (0.66-1.20) 135/225 1.01 (0.73-1.40) 
 4 (35.3 –< 42.1) 123/214 0.80 (0.59-1.09) 123/254 0.83 (0.60-1.16) 
 5 (≥ 42.1) 93/188 0.71 (0.50-1.00) 143/277 0.99 (0.67-1.30) 
   P-trend=0.02  P-trend=0.37 
  P-interaction=0.86 
DMG 1 (< 2.9) 141/243 Reference  130/219 Reference  
(µmol/L) 2 (2.9 –< 3.3) 133/213 1.06 (0.78-1.44) 134/238 0.93 (0.68-1.27) 
 3 (3.3 –< 3.9) 155/241 1.10 (0.81-1.48) 133/231 0.98 (0.71-1.34) 
 4 (3.9 –< 4.6) 151/208 1.25 (0.92-1.71) 126/259 0.78 (0.57-1.07) 
 5 (≥ 4.6) 141/251 0.93 (0.68-1.28) 121/215 0.90 (0.65-1.25) 
   P-trend=0.94  P-trend=0.29 
  P-interaction=0.28 
* Quintiles are based on the distribution of serum concentrations among controls 
**Unconditional logistic regression with case-control matching factors sex, age, and study center modeled as co-variates, 
adjusted for BMI, smoking status, physical activity, alcohol consumption, and intakes of energy, fibre, red meat, and processed 
meat 
